What is the current market value of Dr Oz's iherb stock?

1. What the filings actually say — ranges, not a share price

The clearest reporting draws on Oz’s ethics disclosure and related letters: his iHerb holding is reported as vested RSUs valued between $5 million and $25 million, and the public documents use ranges rather than exact dollar amounts or per‑share prices ^{[1] [2]}. News outlets including KPBS, The New York Times and the Associated Press describe the same $5–$25 million band, reflecting the disclosure’s format ^{[1] [2] [3]}.

2. Why you won’t find a “current market value” like a public stock quote

iHerb is treated in the reporting as a private company; when holdings are in private firms, ethics disclosures commonly list ranges and leave out per‑share market quotes because there is no public market price to report ^{[2] [1]}. The New York Times explicitly notes the company is private and that the filing’s range leaves the exact valuation unclear ^[2].

3. Conflicting language on whether he’ll divest or retain some holdings

Oz pledged in an ethics letter to sell vested RSUs “as soon as practicable but not later than 90 days after confirmation,” and to forfeit unvested RSUs, but reporting highlights ambiguous language that might allow him to retain some interest until a liquidity event such as an IPO or acquisition ^{[4] [1] [2]}. The Times and FierceHealthcare both point to ambiguity in the filing that leaves open the possibility he could hold some iHerb stock until the company goes public or is bought ^{[2] [5]}.

4. Independent reporting consolidates the same estimate — multiple outlets, same band

Major outlets reproduced the $5–$25 million range: KPBS, AP, The New York Times, Bloomberg summaries, and regional papers all reference that same range from the Office of Government Ethics disclosure ^{[1] [3] [2] [4] [6]}. That convergence shows consensus on the disclosure’s reported range, not on any precise market valuation.

5. Social posts and commentary sometimes state “$25M” as a headline figure

Social posts and some summaries use the top of the disclosure range and label it “$25 million” for emphasis, but those posts generally draw from the same filings and do not provide new, verifiable market pricing ^{[7] [4]}. The difference is stylistic: journalists and social accounts sometimes quote the maximum listed value while reporters note the original range ^{[3] [2]}.

6. What’s missing from current reporting — limits you should note

Available sources do not provide any precise per‑share price, transaction data, or post‑filing sale receipts that would let a reader compute an exact market value today; they rely on the ethics disclosure’s ranges and on the private status of iHerb ^{[2] [1]}. If you want a precise market value, current reporting does not include an IPO valuation, a purchase price, or evidence that Oz completed divestiture at a known price ^{[1] [3]}.

7. Competing viewpoints and the ethics angle

Ethics experts and some reporters flagged the ambiguity as concerning: Richard Painter, a former White House ethics lawyer, told reporters the iHerb language is “ambiguous” and that Oz would need to clarify he’d be “completely out” of the company — signaling watchdog skepticism that the pledge, as written, might allow lingering financial ties ^[1]. At the same time, Oz’s pledge to divest vested RSUs within 90 days is also reported, showing he stated an intent to remove holdings in a finite period ^{[3] [4]}.

8. Bottom line for readers seeking a dollar figure

Current, cited reporting establishes only a disclosed range of $5 million to $25 million for Oz’s vested iHerb RSUs and confirms the company’s private status; it does not provide a current, exact market value or per‑share quote ^{[1] [2] [3]}. For a precise valuation you would need either a public market price (iHerb IPO) or documentation of an actual sale with a stated price — neither of which appears in the available reporting ^{[2] [1]}.